Common Contracts
18 similar At-the-Market Sales Agreement contracts by Inmune Bio, Inc., Zosano Pharma Corp, Atlanticus Holdings Corp, others
BARNES & NOBLE EDUCATION, INC. UP TO $40,000,000 OF COMMON STOCK (PAR VALUE $0.01 PER SHARE) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • September 20th, 2024 • Barnes & Noble Education, Inc. • Retail-miscellaneous shopping goods stores • New York
Barnes & Noble Education, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
ATLANTICUS HOLDINGS CORPORATION UP TO $50,000,000 OF COMMON STOCK (no par value per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • January 2nd, 2024 • Atlanticus Holdings Corp • Personal credit institutions • New York
Atlanticus Holdings Corporation, a Georgia corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
At-the-market SALES AGREEMENTAt-the-Market Sales Agreement • May 16th, 2023 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
PERSONALIS, INC. UP TO $100,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • January 3rd, 2022 • Personalis, Inc. • Services-medical laboratories • New York
Personalis, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
At-the-market SALES AGREEMENTAt-the-Market Sales Agreement • June 14th, 2021 • OncoCyte Corp • In vitro & in vivo diagnostic substances • New York
OncoCyte Corporation, a California corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC in its capacity as sales agent for the Company (“BTIG” and, together with the Company, the “Parties”), as follows:
At-the-market SALES AGREEMENTAt-the-Market Sales Agreement • March 11th, 2021 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
INmune Bio Inc., a Nevada corporation ( the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • February 5th, 2021 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations • New York
Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC in its capacity as sales agent for the Company (“BTIG” and, together with the Company, the “Parties”), as follows:
MATINAS BIOPHARMA HOLDINGS, INC. UP TO $50,000,000 OF COMMON STOCK (par value $0.0001 per share) At-the-market SALES AGREEMENTAt-the-Market Sales Agreement • July 2nd, 2020 • Matinas BioPharma Holdings, Inc. • Pharmaceutical preparations • New York
Matinas Biopharma Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
ZOSANO PHARMA CORPORATION UP TO $20,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • June 8th, 2020 • Zosano Pharma Corp • Pharmaceutical preparations • New York
Zosano Pharma Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
SFL CORPORATION LTD. UP TO $100,000,000 OF COMMON SHARES (par value $0.01 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • May 14th, 2020 • SFL Corp Ltd. • Deep sea foreign transportation of freight • New York
SFL Corporation Ltd., a Bermuda exempted company (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
INMUNE BIO INC. UP TO $10,000,000 OF COMMON STOCK (par value $0.001 per share) At-the-market SALES AGREEMENTAt-the-Market Sales Agreement • April 17th, 2020 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
INmune Bio Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
SCORPIO TANKERS INC. UP TO $100,000,000 OF COMMON SHARES (par value $0.01 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • November 8th, 2019 • Scorpio Tankers Inc. • Deep sea foreign transportation of freight • New York
Scorpio Tankers Inc., a corporation incorporated under the laws of the Republic of the Marshall Islands (the "Company"), confirms its agreement (this "Agreement") with BTIG, LLC ("BTIG" and, together with the Company, the "Parties"), as follows:
ZOSANO PHARMA CORPORATION UP TO $15,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • August 19th, 2019 • Zosano Pharma Corp • Pharmaceutical preparations • New York
Zosano Pharma Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
BIOLINERX LTD. Up to $30,000,000 of American Depositary Shares, each representing one ordinary share (par value NIS 0.10 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • October 31st, 2017 • BioLineRx Ltd. • Pharmaceutical preparations • New York
BioLineRx Ltd., a corporation formed under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
KALVISTA PHARMACEUTICALS, INC. COMMON STOCK (par value $0.001 per share) AT- THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • July 13th, 2017 • KalVista Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
PULMATRIX, INC. UP TO $11,000,000 OF COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • March 17th, 2017 • Pulmatrix, Inc. • Pharmaceutical preparations • New York
Pulmatrix, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
DARA BIOSCIENCES, INC. UP TO $2,730,000 OF COMMON STOCK (par value $0.01 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • August 19th, 2013 • DARA BioSciences, Inc. • Pharmaceutical preparations • New York
DARA BioSciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
URANIUM RESOURCES, INC. UP TO $15,000,000 OF COMMON STOCK (par value $0.001 per share) AT-THE-MARKET SALES AGREEMENTAt-the-Market Sales Agreement • October 31st, 2011 • Uranium Resources Inc /De/ • Metal mining • New York
URANIUM RESOURCES, INC., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BTIG, LLC (“BTIG” and, together with the Company, the “Parties”), as follows:
